Atlas Trials

Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma

Clinical trial NCT04508647 · COMPLETED

Trial details

NCT number
NCT04508647
Sponsor
University of Colorado, Denver
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Marginal Zone LymphomaFollicular Lymphoma
Start date
2020-11-23
Primary completion
2022-07-14
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.